Verona Pharma plc — Director's Dealing 2023

Oct 24, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Verona Pharma plc (VRNA)
CIK: 0001657312
Period of Report: 2023-10-20

Reporting Person: Poll Claire (General Counsel)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-10-20	Ordinary Shares	A	200000	—	Acquired	2017391	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares	864232	Indirect

Footnotes

F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F2: Represents an award of Restricted Share Units ("RSUs"), each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer. The RSUs vest over four years, with 50,000 RSUs vesting on November 1, 2024 and the balance vesting in 12 equal quarterly installments thereafter.

F3: Consists of (i) 1,671,672 Ordinary Shares underlying RSUs (which are represented by 208,959 ADSs); (ii) 345,712 Ordinary Shares underlying 43,214 ADSs and (iii) 7 Ordinary Shares.

F4: Held by a family trust of which (a) the Reporting Person and spouse are trustees and (b) the Reporting Person and members of her immediate family are the sole beneficiaries of the trust.